PDF(1222 KB)
Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report
Ping YI, Xing-Xing ZHANG, Tian TANG, Ying WANG, Xiao-Chuan WU, Xing-Fang LI
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (5) : 613-617.
PDF(1222 KB)
PDF(1222 KB)
Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report
The patient, an 11-year-old girl, was admitted with recurrent fever for 20 days, worsening with abdominal distension for 7 days. Upon admission, she presented with recurrent fever, lymphadenopathy, hepatosplenomegaly, polyserositis, and multiple organ dysfunction. Lymph node pathology and clinical manifestations confirmed the diagnosis of idiopathic multicentric Castleman disease-TAFRO syndrome. Treatment with siltuximab combined with glucocorticoids was initiated, followed by maintenance therapy with tocilizumab. The patient is currently in complete clinical remission. Therefore, once a child is diagnosed with idiopathic multicentric Castleman disease -TAFRO syndrome, early use of siltuximab should be considered for rapid disease control, followed by tocilizumab for maintenance therapy.
Castleman disease / TAFRO syndrome / Siltuximab / Tocilizumab
| 1 |
中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国CASTLEMAN病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(7): 529-534. PMCID: PMC8408489. DOI: 10.3760/cma.j.issn.0253-2727.2021.07.001 .
|
| 2 |
|
| 3 |
|
| 4 |
|
| 5 |
|
| 6 |
|
| 7 |
|
| 8 |
|
| 9 |
张路, 李剑. 罕见病Castleman病的靶向治疗药物司妥昔单抗[J]. 中国医药导刊, 2022, 24(4): 299-304. DOI: 10.3969/j.issn.1009-0959.2022.04.001 .
|
| 10 |
刘海玲, 范磊, 李建勇. Castleman病的诊疗进展[J]. 中华血液学杂志, 2020, 41(8): 697-700. PMCID: PMC7525180. DOI: 10.3760/cma.j.issn.0253-2727.2020.08.017 .
|
| 11 |
|
| 12 |
|
| 13 |
|
| 14 |
|
| 15 |
陈航, 朱俪, 丁胜男, 等. 司妥昔单抗/托珠单抗治疗HHV-8阴性多中心型Castleman病的疗效及安全性单中心回顾性分析[J]. 中国医药指南, 2024, 22(31): 44-47. DOI: 10.15912/j.issn.1671-8194.2024.31.013 .
|
易萍负责数据收集、整理和分析、论文撰写;张星星负责文章的构思、设计与修改;唐甜、王英负责辅助数据收集、整理和分析;李杏芳及吴小川负责文章最终提供修改意见。